The Montana Cancer Consortium (MCC) consists of two components (the central data management office in Billings and one component from Great Falls) with eight affiliates [Missoula (2), Helena (1), Kalispell (2), Butte (1), Bozeman (1) and Great Falls (1).] MCC is composed of 44 physicians, which includes all medical and radiation oncologists within the state. The Consortium encompasses a catchment area which includes the entire state of Montana with extension into Wyoming, Idaho, and the Dakotas (some 150,000 sq. miles/population of 903,000). This area is uniquely rural, as well as home to Native Americans from eight reservations. Objective l: Accrual. MCC has named the Southwest Oncology Group (SWOG), the National Surgical Breast and Bowel Project (NSABP), and the Radiation Therapy Oncology Group (RTOG) as primary research bases. MCC estimates a 5% increase per year in accrual to treatment clinical trials. Cancer control accrual for the SELECT trial is estimated at 50 participants per year; and the STAR trial has an estimate of 20 new participants per year. Objective 2: Quality. MCC has centralized data management for this large geographic area to one office in Billings. Centralization facilitates registrations and data management. A quality assurance program has been implemented to facilitate registrations and submission of quality data in a timely manner. The consortium has consolidated into two Institutional Review Boards and two pharmacies. Objective 3: Access. The cooperative effort of the MCC with hospital and health care providers from Montana and surrounding states improves access to state-of-the-art cancer treatment and prevention for an extensive, largely rural population. The network of MCC physicians provides a higher profile for clinical trials, which will create a stimulus to increased accrual. By promoting protocol participation in this geographically unique area and its inclusion of the minority component, MCC provides an excellent site for diffusion of knowledge and improved cancer care in a consortium, which is essential to achieve the NCI's CCOP intent.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
2U10CA067575-09
Application #
6618600
Study Section
Special Emphasis Panel (ZCA1-SRRB-E (J1))
Program Officer
O'Mara, Ann M
Project Start
1995-09-18
Project End
2008-05-31
Budget Start
2003-07-01
Budget End
2004-05-31
Support Year
9
Fiscal Year
2003
Total Cost
$495,189
Indirect Cost
Name
Montana Cancer Consortium
Department
Type
DUNS #
802713917
City
Billings
State
MT
Country
United States
Zip Code
59101
Cheng, Heather H; Plets, Melissa; Li, Hongli et al. (2018) Circulating microRNAs and treatment response in the Phase II SWOG S0925 study for patients with new metastatic hormone-sensitive prostate cancer. Prostate 78:121-127
Samlowski, Wolfram E; Moon, James; Witter, Merle et al. (2017) High frequency of brain metastases after adjuvant therapy for high-risk melanoma. Cancer Med 6:2576-2585
Wozniak, Antoinette J; Moon, James; Thomas Jr, Charles R et al. (2015) A Pilot Trial of Cisplatin/Etoposide/Radiotherapy Followed by Consolidation Docetaxel and the Combination of Bevacizumab (NSC-704865) in Patients With Inoperable Locally Advanced Stage III Non-Small-Cell Lung Cancer: SWOG S0533. Clin Lung Cancer 16:340-7
Ramanathan, Ramesh K; McDonough, Shannon L; Kennecke, Hagen F et al. (2015) Phase 2 study of MK-2206, an allosteric inhibitor of AKT, as second-line therapy for advanced gastric and gastroesophageal junction cancer: A SWOG cooperative group trial (S1005). Cancer 121:2193-7
Mata, Douglas A; Groshen, Susan; Von Rundstedt, Friedrich-Carl et al. (2015) Variability in surgical quality in a phase III clinical trial of radical cystectomy in patients with organ-confined, node-negative urothelial carcinoma of the bladder. J Surg Oncol 111:923-8
Lee, Sylvia M; Moon, James; Redman, Bruce G et al. (2015) Phase 2 study of RO4929097, a gamma-secretase inhibitor, in metastatic melanoma: SWOG 0933. Cancer 121:432-440
Goldkorn, Amir; Ely, Benjamin; Tangen, Catherine M et al. (2015) Circulating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421: a phase III metastatic castration resistant prostate cancer trial. Int J Cancer 136:1856-62
Blumenthal, Deborah T; Rankin, Cathryn; Stelzer, Keith J et al. (2015) A Phase III study of radiation therapy (RT) and O?-benzylguanine + BCNU versus RT and BCNU alone and methylation status in newly diagnosed glioblastoma and gliosarcoma: Southwest Oncology Group (SWOG) study S0001. Int J Clin Oncol 20:650-8
Yu, Evan Y; Li, Hongli; Higano, Celestia S et al. (2015) SWOG S0925: A Randomized Phase II Study of Androgen Deprivation Combined With Cixutumumab Versus Androgen Deprivation Alone in Patients With New Metastatic Hormone-Sensitive Prostate Cancer. J Clin Oncol 33:1601-8
Othus, Megan; Appelbaum, Frederick R; Petersdorf, Stephen H et al. (2015) Fate of patients with newly diagnosed acute myeloid leukemia who fail primary induction therapy. Biol Blood Marrow Transplant 21:559-64

Showing the most recent 10 out of 151 publications